Optruma (Raloxifene Hydrochloride)

Raloxifene Hydrochloride, the active ingredient in Optruma, is a Selective Estrogen Receptor Modulator (SERM) presented as a unknown/unknown for oral use. It treats postmenopausal osteoporosis and reduces breast cancer risk in postmenopausal women. GNH USA supplies Optruma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Optruma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Optruma is a SERM that acts on bone metabolism and estrogen‑dependent tissues.

- Postmenopausal osteoporosis: Increases the risk‑adjusted bone density and reduces fracture incidence. - Invasive breast cancer risk reduction: Low the likelihood of developing invasive breast cancer in post‑  ... (continues)